보고서 요약(국문)

개요
전 세계 바렛 식도 치료 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
바렛 식도는 식도(입과 위를 연결하는 음식물이 지나가는 관)의 정상적인 중층 편평 상피(분홍색 점막)가 위산 역류로 손상되어 두꺼워지고 붉어지는 질환입니다. 이는 내시경 검사에서 확인되며, 병리학적으로는 장 상피세포의 형성과 유사한 두꺼운 세포가 존재하는 장상피화생으로 확진됩니다.

위식도 역류 질환(GERD)은 위산과 담즙이 식도와 위 사이에 위치한 중요한 밸브인 하부식도괄약근(LES)을 통해 역류하는 질환입니다. LES는 위 내용물이 식도로 역류하는 것을 막는 역할을 합니다. 위 점막은 소화에 필요한 산성 환경을 견딜 수 있는 점액성 원주상피로 구성되어 있는 반면, 식도 점막은 편평상피로 구성되어 있습니다.
시장 동향: 성장 동인 및 제약 요인
위식도 역류 질환(GERD) 유병률 증가
위식도 역류 질환 유병률 증가는 예측 기간 동안 시장 성장을 견인하는 주요 요인 중 하나입니다. 위식도 역류 질환(GERD)의 유병률은 전 세계적으로 다양하며, 남미 23%, 북미 18~28%, 호주 12%, 동아시아 2~7%, 유럽 9~26%, 중동 9~33%로 추정됩니다. 특히 동아시아와 북미 지역에서 1995년 이후 GERD 유병률이 크게 증가했다는 증거가 있습니다. 사우디아라비아의 GERD 유병률은 29~45%로 나타났습니다. 사우디아라비아 인구의 GERD 유병률은 서구 국가 및 동아시아 국가에 비해 상당히 높습니다.
또한, 치료 기술의 발전, 사람들의 생활 방식 변화, 의료 인프라 투자 증가, 노인 인구 증가, 연구 개발 증가 등이 예측 기간 동안 시장 성장을 더욱 촉진할 것입니다.
시장 동향: 제약 요인
질병과 관련된 합병증은 시장 성장을 저해하는 주요 제약 요인 중 하나입니다. 바렛 식도 환자는 식도암 발병 위험이 더 높습니다. 식도 세포가 전암성 변화를 겪은 환자의 경우에도 위험은 미미합니다. 다행히 바렛 식도 환자에게서 식도암이 발생하는 경우는 드뭅니다. 또한, 인식 부족, 높은 치료 비용, 진단상의 어려움, 제한적인 치료 옵션 등은 예측 기간 동안 시장 성장을 저해하는 요인으로 작용할 것입니다.
세분화 분석
전 세계 바렛 식도 치료 시장은 유형, 치료 방법, 약물, 판매 채널 및 지역별로 세분화됩니다.
유형별 세그먼트 중 저등급 이형성증이 시장 점유율의 약 41.2%를 차지했습니다.
저등급 이형성증은 예측 기간 동안 시장을 주도할 것으로 예상됩니다. 저등급 이형성증은 일부 세포가 비정상적으로 보이는 상태를 의미합니다. 이 세포들은 어떤 면에서는 암세포처럼 보일 수 있지만, 암과는 달리 신체의 다른 부위로 전이될 가능성은 없습니다. 이는 식도의 매우 초기 단계의 전암성 병변입니다.
예를 들어, 혁신적인 검사를 통해 환자 치료를 안내하는 기업인 Castle Biosciences, Inc.는 2023년 8월, The American Journal of Gastroenterology에 발표된 새로운 연구 결과를 통해 조직사이퍼 바렛 식도 검사 결과를 활용하여 저등급 이형성증(LGD)을 가진 바렛 식도 환자의 치료 결정을 크게 개선하고 건강 결과를 향상시킬 수 있음을 보여주었습니다.
지역 분석
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
북미는 비만, 위식도 역류 질환(GERD), 흡연 등의 요인으로 인해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다. 인구 고령화가 지속됨에 따라 이형성증을 동반한 바렛 식도 치료에 대한 수요가 증가할 것으로 예상됩니다. 이에 따라 북미에서는 고주파 절제술(RFA), 냉동 요법, 내시경 점막 절제술(EMR)을 포함한 이형성증을 동반한 바렛 식도에 대한 내시경 기술 및 치료법이 크게 발전했습니다.
또한 북미는 잘 훈련된 의료진과 첨단 의료 기술에 대한 접근성을 갖춘 강력한 의료 인프라를 보유하고 있습니다. 예를 들어, 2023년 8월 기준으로 미국을 비롯한 서구 국가에서 식도암과 위암 발병률은 지난 50년 동안 크게 증가했습니다.
식도선암과 위선암은 치사율이 매우 높은 암입니다. 그러나 연구 과학자 조엘 루벤스타인은 예방 조치가 도움이 될 수 있다고 제안합니다. 선별 검사를 통해 바렛 식도와 같은 암 전단계 변화를 조기에 발견할 수 있으며, 이는 장기간 위식도 역류 질환(GERD) 환자에게서 진단될 수 있습니다.

COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 소화기내과 서비스에 심각한 영향을 미쳤습니다. 코로나바이러스 감염률이 증가함에 따라 많은 전문 기관에서는 응급 및 필수 시술을 제외한 모든 내시경 검사를 즉시 중단할 것을 권고했습니다. 상부 위장관 내시경 검사는 SARS-CoV-2 바이러스의 에어로졸화 및 전파 가능성이 높아 고위험 시술로 간주되었습니다.
경쟁 환경
바렛 식도 치료 시장의 주요 글로벌 업체로는 Novartis AG, Advacarepharma, Apotex, Takeda Pharmaceutical Company Limited, Woodward Pharma Services LLC, Steris, Medtronic Plc, Stryker, Boston Scientific, Olympus 등이 있습니다.

주요 동향
 2022년 8월, 미국 소화기학회(American College of Gastroenterology)는 바렛 식도에 대한 새로운 가이드라인을 발표했습니다. 이 가이드라인은 내시경 검사 외에도 선별 검사 방법을 확대하고, 단절 바렛 식도에 대한 감시 빈도를 높이며, 내시경 치료 센터의 시술 건수 기준을 도입할 것을 제안합니다.

 2022년 1월, 연구진은 바렛 식도의 세포 기원을 밝혀냈습니다. 다나-파버 암 연구소(Dana-Farber Cancer Institute) 과학자들이 수행한 두 건의 최근 연구는 바렛 식도의 기원에 대한 오랜 오해를 바로잡았으며, 이를 통해 식도암 위험을 낮추는 새로운 치료 또는 예방 방법을 제시할 수 있습니다.

 2020년 6월, 세르노스틱스(Cernostics)는 비이형성 바렛 식도 환자에서 식도암으로의 진행 위험을 예측하는 조직사이퍼(tissuecypher)의 성능에 대한 맹검 독립 검증 결과를 발표했습니다.

보고서를 구매해야 하는 이유?

• 전 세계 바렛 식도 치료 시장을 유형, 치료법, 약물, 판매 채널 및 지역별로 세분화하여 시각화하고 주요 상업 자산과 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.
• 모든 세그먼트를 포함한 바렛 식도 치료 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

전 세계 바렛 식도 치료 시장 보고서는 약 69개의 표, 70개의 그림, 185페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Barett’s Esophagus Treatment Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
Barrett's esophagus is a condition in which the normal stratified squamous epithelium (pink lining or mucosal lining) of the oesophagus (food/swallowing pipe that connects mouth and stomach) is damaged by acid reflux and thickens and reddens, as detected on endoscopic examination and pathologically confirmed by the presence of intestinal metaplasia columnar epithelium (the presence of thick cells similar to those present in the intestine).
GERD is a condition, where the acid and bile from the stomach come back up through the lower oesophageal sphincter (LES), a critically important valve, present between the oesophagus and the stomach that prevents the reflux of gastric contents back into the oesophagus. The lining of the stomach is made of mucinous columnar epithelium, which can handle the acidic environment needed for digestion, whereas the lining of the oesophagus, on the other hand, is made of squamous epithelium.
Market Dynamics: Drivers and Restraints
Rise in the prevalence of gastroesophageal reflux disease (GERD)
The rise in the prevalence of gastroesophageal reflux diseases is one of the factors that drive the market growth during the forecast period. The prevalence of GERD is varied globally, which is estimated to be 23% in South America, 18% to 28% in North America, 12% in Australia, 2% to 7% in East Asia, 9% to 26% in Europe, and 9% to 33% in the Middle East the evidence suggests that the prevalence of GERD has significantly increased since 1995, especially in East Asia and North America. The prevalence of GERD in Saudi Arabia varied from 29% to 45%. In the Saudi population, the prevalence of GERD is substantially higher compared to western countries and East Asian countries.
Furthermore, technological advancements in treatments, changing lifestyles of people, increasing investment in healthcare infrastructure, rise in the number of geriatric populations, increasing research and developments and other will further drive the market growth further during the forecast period.
Market Dynamics: Restraint
Complications associated with the disease is one of the major restraining factors that hampers the market growth. Those who have barrett's esophagus are more likely to get esophageal cancer. Even in patients whose esophageal cells have undergone precancerous alterations, the danger is minimal. Fortunately, esophageal cancer seldom occurs in patients with barrett's esophagus. Also, lack of awareness, high cost of treatment, diagnostic challenges, limited treatment options and others will also be the restraint factors that hamper the market growth during the forecast period.
Segment Analysis
The global barett’s esophagus treatment is segmented based on type, treatment, medication, sales channel and region.
The low-grade dysplasia from the type segment accounted for approximately 41.2% of the market share
The low-grade dysplasia from the type segment accounted for 41.2% and it is expected to be dominated during the forecast period. Low-grade dysplasia means that some of the cells look abnormal. These cells may look like cancer cells in some ways, but unlike cancer, they don’t have the ability to spread to other parts of your body. This is a very early pre-cancer of the esophagus.
For instance, in August 2023, Castle Biosciences, Inc. a company improving health through innovative tests that guide patient care, stated a new study published in The American Journal of Gastroenterology showing how use of tissuecypher barrett’s esophagus test results can significantly improve management decisions for barrett’s esophagus patients with low-grade dysplasia (LGD) to improve health outcomes.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the factors such as obesity, gastroesophageal reflux disease (GERD), and smoking. As the population continues to age, the demand for treatment for Barrett's esophagus with dysplasia is expected to increase. Due to this, there have been significant advancements in endoscopic technologies and treatments for barrett's esophagus with dysplasia in North America, including radiofrequency ablation (RFA), cryotherapy, and endoscopic mucosal resection (EMR).
Furthermore, North America has a strong healthcare infrastructure, with well-trained healthcare providers and access to advanced medical technologies. For instance, in August 2023, esophageal and stomach cancer rates have increased significantly in the US and other western countries over the past five decades.
Esophageal adenocarcinoma and GCA are highly fatal cancers. However, research scientist Joel Rubenstein suggests that preventative measures can help. Screening can identify pre-cancerous changes in patients, such as barrett's esophagus, which can be diagnosed in those with long-term gastroesophageal reflux disease (GERD).
COVID-19 Impact Analysis
The COVID-19 pandemic has dramatically impacted gastroenterology services worldwide. As coronavirus infection rates rose, many professional bodies advised that all endoscopy, except emergency and essential procedures, be stopped immediately. Upper gastrointestinal endoscopy was considered a high-risk procedure due to a greater potential for aerosolization and transmission of the SARS-CoV-2 virus .
Competitive Landscape
The major global players in the barett’s esophagus treatment market include Novartis AG, Advacarepharma, Apotex, Takeda Pharmaceutical Company Limited, Woodward Pharma Services LLC,Steris, Medtronic Plc, Stryker, Boston Scientific, Olympus and among others.
Key Developments
 In August 2022, the American College of Gastroenterology released new guidelines for Barrett's esophagus, which suggest expanding the screening methods beyond endoscopic procedures, increasing the frequency of surveillance for short-segment Barrett's esophagus, and implementing volume criteria for endoscopic therapy centres.
 In January 2022, Researchers unmask the cellular source of barrett’s esophagus. Two recent studies by Dana-Farber Cancer Institute scientists correct a longstanding misconception about the origins of barrett’s esophagus, and in doing so may point to new avenues of treatment or prevention to lower the risk of esophageal cancer.
 In June 2020, Cernostics stated blinded, independent validation of tissuecypher performance for predicting risk of progression to esophageal cancer in patients with non-dysplastic be.
Why Purchase the Report?
• To visualize the global barett’s esophagus treatment market segmentation-based type, treatment, medication, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of barett’s esophagus treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global barett’s esophagus treatment market report would provide approximately 69 tables, 70 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by Medication
3.4. Snippet by Sales Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Driver
4.1.1.1. Rise in the prevalence of gastroesophageal reflux disease (GERD)
4.1.1.2. Rise in the technology advancements in treatment options
4.1.2. Restraints
4.1.2.1. Complications associated with the disease
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Low Grade Dysplasia*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. High-Grade Dysplasia
7.4. No Dysplasia
8. By Treatment Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Endoscopic Resection*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Radiofrequency Ablation
8.4. Esophagectomy
8.5. Photodynamic Therapy
8.6. Cryotherapy
9. By Medication
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Antacids*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Protein Pump Inhibitors
9.4. Histamine Blockers
9.5. Prokinetic Agents
10. By Sales Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.1.2. Market Attractiveness Index, By Sales Channel
10.2. End User*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Distribution Channel
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Novartis AG
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Advacarepharma
13.3. Apotex
13.4. Takeda Pharmaceutical Company Limited
13.5. Woodward Pharma Services LLC
13.6. Steris
13.7. Medtronic Plc
13.8. Stryker
13.9. Boston Scientific
13.10. Olympus
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Novartis AG, 4. Key Developments, Advacarepharma, Apotex, Takeda Pharmaceutical Company Limited, Woodward Pharma Services LLC, Steris, Medtronic Plc, Stryker, Boston Scientific, Olympus

표 목록 (Tables)

List of Tables

Table 1 Global Barett’s Esophagus Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Barett’s Esophagus Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Barett’s Esophagus Treatment Market Value, By Medications, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Barett’s Esophagus Treatment Market Value, By Sales Channel, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Barett’s Esophagus Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Barett’s Esophagus Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Barett’s Esophagus Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 8 Global Barett’s Esophagus Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Barett’s Esophagus Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 10 Global Barett’s Esophagus Treatment Market Value, By Medications, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Barett’s Esophagus Treatment Market Value, By Medications, 2021-2030 (US$ Million)

Table 12 Global Barett’s Esophagus Treatment Market Value, By Sales Channel, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Barett’s Esophagus Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 14 Global Barett’s Esophagus Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Barett’s Esophagus Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Barett’s Esophagus Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 17 North America Barett’s Esophagus Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 18 North America Barett’s Esophagus Treatment Market Value, By Medications, 2021-2030 (US$ Million)

Table 19 North America Barett’s Esophagus Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 20 North America Barett’s Esophagus Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Barett’s Esophagus Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 22 South America Barett’s Esophagus Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 23 South America Barett’s Esophagus Treatment Market Value, By Medications, 2021-2030 (US$ Million)

Table 24 South America Barett’s Esophagus Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 25 South America Barett’s Esophagus Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Barett’s Esophagus Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 27 Europe Barett’s Esophagus Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 28 Europe Barett’s Esophagus Treatment Market Value, By Medications, 2021-2030 (US$ Million)

Table 29 Europe Barett’s Esophagus Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 30 Europe Barett’s Esophagus Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Barett’s Esophagus Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Barett’s Esophagus Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Barett’s Esophagus Treatment Market Value, By Medications, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Barett’s Esophagus Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 35 Middle East & Africa Barett’s Esophagus Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Barett’s Esophagus Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Barett’s Esophagus Treatment Market Value, By Medications, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Barett’s Esophagus Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 39 Novartis AG: Overview

Table 40 Novartis AG: Product Portfolio

Table 41 Novartis AG: Key Developments

Table 42 Advacarepharma: Overview

Table 43 Advacarepharma: Product Portfolio

Table 44 Advacarepharma: Key Developments

Table 45 Apotex: Overview

Table 46 Apotex: Product Portfolio

Table 47 Apotex: Key Developments

Table 48 Takeda Pharmaceutical Company Limited: Overview

Table 49 Takeda Pharmaceutical Company Limited: Product Portfolio

Table 50 Takeda Pharmaceutical Company Limited: Key Developments

Table 51 Woodward Pharma Services LLC: Overview

Table 52 Woodward Pharma Services LLC: Product Portfolio

Table 53 Woodward Pharma Services LLC: Key Developments

Table 54 Steris: Overview

Table 55 Steris: Product Portfolio

Table 56 Steris: Key Developments

Table 57 Medtronic Plc: Overview

Table 58 Medtronic Plc: Product Portfolio

Table 59 Medtronic Plc: Key Developments

Table 60 Stryker: Overview

Table 61 Stryker: Product Portfolio

Table 62 Stryker: Key Developments

Table 63 Boston Scientific : Overview

Table 64 Boston Scientific : Product Portfolio

Table 65 Boston Scientific : Key Developments

Table 66 Olympus: Overview

Table 67 Olympus: Product Portfolio

Table 68 Olympus: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Barett’s Esophagus Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Barett’s Esophagus Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 4 Global Barett’s Esophagus Treatment Market Share, By Medications, 2022 & 2030 (%)

Figure 5 Global Barett’s Esophagus Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 6 Global Barett’s Esophagus Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Barett’s Esophagus Treatment Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 8 No Dysplasia Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Low Grade Dysplasia Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 High Grade Dysplasia Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Global Barett’s Esophagus Treatment Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 12 Endoscopic Resection Treatment in Global Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 13 Radiofrequency Ablation Treatment in Global Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Esophagectomy Treatment in Global Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Photodynamic Therapy Treatment in Global Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Cryotherapy Treatment in Global Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 17 Global Barett’s Esophagus Treatment Market Y-o-Y Growth, By Medications, 2022-2030 (%)

Figure 18 Antacids Medications in Global Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Protein Pump Inhibitors Medications in Global Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Histamine Blockers Medications in Global Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 21 Prokinetic Agents Medications in Global Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Global Barett’s Esophagus Treatment Market Y-o-Y Growth, By Sales Channel, 2022-2030 (%)

Figure 23 End User Sales Channel in Global Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 Distribution Channel Sales Channel in Global Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 Global Barett’s Esophagus Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 26 North America Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 Asia-Pacific Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 28 Europe Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 29 South America Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 30 Middle East and Africa Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 31 North America Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 32 North America Barett’s Esophagus Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 33 North America Barett’s Esophagus Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 34 North America Barett’s Esophagus Treatment Market Share, By Medications, 2022 & 2030 (%)

Figure 35 North America Barett’s Esophagus Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 36 North America Barett’s Esophagus Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 37 South America Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 38 South America Barett’s Esophagus Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 39 South America Barett’s Esophagus Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 40 South America Barett’s Esophagus Treatment Market Share, By Medications, 2022 & 2030 (%)

Figure 41 South America Barett’s Esophagus Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 42 South America Barett’s Esophagus Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 43 Europe Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 44 Europe Barett’s Esophagus Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 45 Europe Barett’s Esophagus Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 46 Europe Barett’s Esophagus Treatment Market Share, By Medications, 2022 & 2030 (%)

Figure 47 Europe Barett’s Esophagus Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 48 Europe Barett’s Esophagus Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 49 Asia-Pacific Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 50 Asia-Pacific Barett’s Esophagus Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 51 Asia-Pacific Barett’s Esophagus Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 52 Asia-Pacific Barett’s Esophagus Treatment Market Share, By Medications, 2022 & 2030 (%)

Figure 53 Asia-Pacific Barett’s Esophagus Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 54 Asia-Pacific Barett’s Esophagus Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 55 Middle East & Africa Barett’s Esophagus Treatment Market Value, 2021-2030 (US$ Million)

Figure 56 Middle East & Africa Barett’s Esophagus Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 57 Middle East & Africa Barett’s Esophagus Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 58 Middle East & Africa Barett’s Esophagus Treatment Market Share, By Medications, 2022 & 2030 (%)

Figure 59 Middle East & Africa Barett’s Esophagus Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 60 Novartis AG: Financials

Figure 61 Advacarepharma: Financials

Figure 62 Apotex: Financials

Figure 63 Takeda Pharmaceutical Company Limited: Financials

Figure 64 Woodward Pharma Services LLC: Financials

Figure 65 Steris: Financials

Figure 66 Medtronic Plc: Financials

Figure 67 Stryker: Financials

Figure 68 Boston Scientific : Financials

Figure 69 Olympus: Financials

글로벌 바렛 식도 치료 시장 – 2023-2030

Global Barett’s Esophagus Treatment Market -2023-2030